Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

被引：0
|
作者：
Konecny, Gottfried E.
Hendrickson, Andrea Elisabeth Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael F.
Letrent, Stephen P.
Slamon, Dennis J.
机构：
[1] Univ Calif Los Angeles Med Ctr, Santa Monica, CA USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA
[4] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA
[5] Vanadro LLC, Urbandale, IA USA
[6] Univ Southern Calif, Los Angeles, CA USA
[7] Translat Res Oncol US, Los Angeles, CA USA
[8] TORL Biotherapeut, Culver City, CA USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3082
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
    Meric-Bernstam, F.
    Naito, Y.
    Gaillard, S.
    Shimoi, T.
    Chung, V.
    Davis, A. A.
    Proia, T.
    Ayyoub, A.
    Kulkarni, M.
    Upadhyay, S.
    Miller, N.
    Luheshi, N.
    Varga, A.
    Oh, D-Y.
    Mileshkin, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S485 - S486
  • [42] First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.
    Ameratunga, Malaka
    Harvey, R. Donald
    Mau-Sorensen, Morten
    Thistlethwaite, Fiona
    Forssmann, Ulf
    Gupta, Manish
    Johannsdottir, Hrefna
    Ramirez-Andersen, Terrie
    Bohlbro, Mika Linette
    Losic, Nedjad
    Ervin-Haynes, Annette L.
    Lopez, Juanita Suzanne
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors
    Meric-Bernstam, Funda
    Oh, Do-Youn
    Naito, Yoichi
    Shimizu, Toshio
    Chung, Vincent
    Park, Haeseong
    Gaillard, Stephanie
    Wang, Fujun
    Cooper, Zachary A.
    Kinneer, Krista
    Rebelatto, Marlon
    Kirby, Lyndon
    Luheshi, Nadia
    Miller, Neil
    Varga, Andreea
    Mileshkin, Linda R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors
    Coward, Jim
    Kichenadasse, Ganessan
    Park, John J.
    Parakh, Sagun
    Richardson, Gary Edward
    Voskoboynik, Mark
    Powderly, John D., II
    Song, Zhengbo
    Liu, Shutong
    Huang, Yaling
    Liu, Shu-Hui
    Meng, Xun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] First-in-human phase 1 study of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors
    Wang, Yong-Sheng
    Jiang, Yu
    Sun, Meili
    Liang, Xu
    Li, Huiping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors.
    Borazanci, Erkut Hasan
    Janku, Filip
    Hamilton, Erika P.
    Thomas, Jacob Stephen
    Sen, Shiraj
    Fu, Siqing
    Wheeler, Catherine A.
    Wages, David S.
    Matsumoto, Takeshi
    Shimoyama, Susumu
    Yamada, Naoki
    Subach, Ruth Ann
    Madden, Timothy
    Johansen, Mary
    Maier, Gary
    Cheung, Kin
    Korn, Ron
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors.
    Patnaik, Amita
    Call, Justin
    McKean, William Bennion
    Rasco, Drew W.
    Oppelt, Peter John
    Kapoor, Varun N.
    Kumar, Vinay
    Rajasekaran, Narendiran
    Tang, Helen
    Reichert, Vienna Lynn
    Masia, Ricard
    Clement, Jessica
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] FIRST-IN-HUMAN PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: INITIAL PHASE 1 RESULTS
    Friedman, Claire
    Ascierto, Paolo
    Davar, Diwakar
    O'Hara, Mark
    Shapira-Frommer, Ronnie
    Dallos, Matthew
    Khemka, Vivek
    James, Lee
    Fischer, Bruce
    Demes, Shilpa
    Li, Li
    Kozicki, Martin
    Ravindran, Palanikumar
    Xu, Ke
    Kollia, Georgia
    Shoukry, Jacqueline
    Yunan, Mona
    Massey, Ashish
    Gutierrez, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A239 - A239
  • [49] BNT211: a Phase 1 Study to determine the Safety and Efficacy of CLDN6 CAR T Cells and CARVAC-mediated in vivo Expansion in Patients with CLDN6-positive advanced solid Tumors
    Haanen, J. B.
    Mackensen, A.
    Koenecke, C.
    Alsdorf, W.
    Wagner-Drouet, E.
    Heudobler, D.
    Borchmann, P.
    Klobuch, S.
    Smit, E.
    Bokemeyer, C.
    Desuki, A.
    Luke, F.
    Wiegert, E.
    Schulz-Eying, C.
    Rengstl, B.
    Preussner, L.
    Tureci, O.
    Sahin, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 43 - 44
  • [50] A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors.
    Johnson, Melissa
    Ulahannan, Susanna
    Vandross, Andrae
    Park, Haeseong
    Faoro, Leo
    Faggioni, Raffaella
    Li, Jing
    Chang, Yu-Lin
    Uttamsingh, Shailaja
    Tolcher, Anthony
    CANCER RESEARCH, 2022, 82 (12)
12345